A PYMNTS Company

US: Judge ordered to reconsider class in Provigil antitrust case

By  |  September 14, 2016

A federal appeals court has ordered a federal judge in Philadelphia to reconsider his order certifying a class of 22 drug wholesalers accusing generic drugmakers Mylan Inc and Ranbaxy Laboratories Ltd of accepting payments from Cephalon Inc to delay generic versions of Cephalon’s wakefulness drug Provigil.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    The 2-1 panel of the 3rd US Circuit Court of Appeals ruled Tuesday that US District Judge Mitchell Goldberg of the Eastern District of Pennsylvania wrongly took into account the fact that the litigation had already lasted nine years when he certified the class to promote judicial efficiency.

    We’d love to be your preferred source for news.

    Please add us to your preferred sources list so our news, data and interviews show up in your feed. Thanks!

    Add as Preferred Source

    Full Content: Reuters

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.